share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-SK bioscience Co., Ltd.(4.6%),SK chemicals Co., Ltd.(4.6%), etc.

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-SK bioscience Co., Ltd.(4.6%),SK chemicals Co., Ltd.(4.6%), etc.

诺瓦瓦克斯医药 | SC 13G/A：超过5%持股股东披露文件(修正)-SK bioscience Co., Ltd.(4.6%),SK chemicals Co., Ltd.(4.6%)等
美股sec公告 ·  06/20 14:38
Moomoo AI 已提取核心信息
Novavax, Inc., a biotechnology company specializing in vaccine development, has experienced a significant change in its shareholder structure. SK bioscience Co., Ltd., SK chemicals Co., Ltd., and SK discovery Co., Ltd., all based in the Republic of Korea, have filed an exit filing with the United States Securities and Exchange Commission, indicating that they are no longer beneficial owners of more than five percent of Novavax's outstanding common stock. This amendment, filed on June 20, 2024, follows a securities subscription agreement dated August 8, 2023, and is based on the number of shares outstanding as of April 30, 2024, as reported in Novavax's Form 10-Q. Each of the reporting companies had shared voting and dispositive power over 6,500,000 shares, representing 4.6% of the class. The exit filing signifies that the companies have ceased to be the beneficial owner of more than five percent of Novavax's shares, a move that could potentially impact the company's stock performance and investor relations.
Novavax, Inc., a biotechnology company specializing in vaccine development, has experienced a significant change in its shareholder structure. SK bioscience Co., Ltd., SK chemicals Co., Ltd., and SK discovery Co., Ltd., all based in the Republic of Korea, have filed an exit filing with the United States Securities and Exchange Commission, indicating that they are no longer beneficial owners of more than five percent of Novavax's outstanding common stock. This amendment, filed on June 20, 2024, follows a securities subscription agreement dated August 8, 2023, and is based on the number of shares outstanding as of April 30, 2024, as reported in Novavax's Form 10-Q. Each of the reporting companies had shared voting and dispositive power over 6,500,000 shares, representing 4.6% of the class. The exit filing signifies that the companies have ceased to be the beneficial owner of more than five percent of Novavax's shares, a move that could potentially impact the company's stock performance and investor relations.
生物技术公司诺瓦瓦克斯医药在疫苗开发领域专注，其股东结构发生了重大变化。韩国SK集团旗下的SK bioscience有限公司、SK chemicals有限公司和SK discovery有限公司在美国证券交易所提交了退出申报文件，表明它们不再拥有诺瓦瓦克斯医药流通股中五分之一以上的股份。这一修正案是在2024年6月20日提交的，此前于2023年8月8日签署了证券认购协议并基于截至2024年4月30日的流通股份，在诺瓦瓦克斯医药的第10-Q表格中报告。每个报告公司都共享投票和处分权，占该类别股票的4.6%，即650万股。退出申报表示这些公司已经不再是诺瓦瓦克斯医药五分之一以上股份的有益所有人，这可能会对公司的股票表现和投资者关系产生潜在影响。
生物技术公司诺瓦瓦克斯医药在疫苗开发领域专注，其股东结构发生了重大变化。韩国SK集团旗下的SK bioscience有限公司、SK chemicals有限公司和SK discovery有限公司在美国证券交易所提交了退出申报文件，表明它们不再拥有诺瓦瓦克斯医药流通股中五分之一以上的股份。这一修正案是在2024年6月20日提交的，此前于2023年8月8日签署了证券认购协议并基于截至2024年4月30日的流通股份，在诺瓦瓦克斯医药的第10-Q表格中报告。每个报告公司都共享投票和处分权，占该类别股票的4.6%，即650万股。退出申报表示这些公司已经不再是诺瓦瓦克斯医药五分之一以上股份的有益所有人，这可能会对公司的股票表现和投资者关系产生潜在影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息